Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Pfizer’s next deals are likely to be longer-term efforts to reload its R&D work rather than big-ticket, late-stage assets, the company’s top executives said Tuesday
Despite uncertainty around HPV vaccine sales in China, Merck CEO Rob Davis said he’s confident the company can “deliver strong growth” and navigate Keytruda’s impending
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Plus, news about Auron Therapeutics, Akribion Therapeutics, Enveric Biosciences and Valerio Therapeutics: Turnstone Biologics to discontinue TIL studies, “review strategic alternatives”: The company Sign up
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
At long last, the FDA approved Supernus Pharmaceuticals’ Parkinson’s disease treatment, which will be marketed as Onapgo. Onapgo is now approved … Sign up to